Evidence map›Paper›PMID 42558165›Full record

ArticleFrontiers in systems biology2026

Mapping cancer dynamics from normal tissue to malignancy using N- and T-gene expression markers.

Gabriel Gil, Rolando Perez, Augusto Gonzalez

Abstract read
In one paragraph

Article in Frontiers in systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gabriel GilInstitute of Cybernetics, Mathematics and Physics, Havana, Cuba.
Rolando PerezCenter for Molecular Immunology, Havana, Cuba.
Augusto GonzalezInstitute of Cybernetics, Mathematics and Physics, Havana, Cuba.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Carcinogenesis involves two major phases: somatic evolution of normal tissue toward tumor formation, followed by tumor progression toward malignancy. Standard differential expression analysis cannot assign genes specifically to either phase. We introduce N- and T-genes with exclusive expression intervals for normal tissue and tumors, respectively, as markers that could potentially map these dynamics. Methods: Using TCGA RNA-Seq data from prostate adenocarcinoma (PRAD), lung adenocarcinoma (LUAD) and liver hepatocellular carcinoma (LIHC), we identify N- and T-genes through statistically significant expression intervals exclusive to normal or tumor samples, respectively. We discretize expression into three states ( Results: Across different cancer types, normal and tumor samples occupy two well-separated attractors in gene-expression space, giving rise to large sets of N- and T-genes. The number of active N-genes decreases continuously as samples move away from the normal attractor, whereas the number of active T-genes increases as samples progress towards the tumor attractor. Large blocks of N-genes are observed, suggesting coordinated multi-gene deactivation events. The combination of staging through the number of active genes with the molecular taxonomy based on panel genes provides a complete description of the somatic evolution of a normal tissue and the progression towards malignancy of tumors. Conclusion: The N- and T-gene framework provides a natural decomposition of carcinogenesis into somatic evolution (loss of N-gene activity) and tumor progression (gain of T-gene activity). Active N- and T-gene counts can be interpreted as tally marks of somatic evolution and tumor progression, respectively, while complete gene panels enable a taxonomy of samples and helps identifying the biological programs active in each sample. The framework is general and applicable across cancer types, although quantitative results depend on the underlying dataset.

Indexed as

carcinogenesisN- and T-genesprostate adenocarcinomasomatic evolutionsystems biologytumor progression

Identifiers

PMID42558165
PMCPMC13437281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.